Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RN564

Phase 1Biologic

RN564 is one of 19 biologic programs targeting Osteopenia. It is currently in Phase 1.

1

Indications

1

Total Trials

0

Active Trials

18

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteopeniaActive, not recruiting

OsteopeniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Osteopenia

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Evista

Estrace

Deltavit

HHyundai Pharmaceutical Co., LTD.

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Forteo

Zometa

Prolia

Boniva

CConrado Roberto Hoffmann Filho

Ozempic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteopenia1 trial

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

Completed· Pfizer logo

Pfizer·Phase 1·NCT01293487·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RN564. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RN564 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RN564. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Pfizer

Related News